Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct comparison of the two blockbuster medications

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.